| Literature DB >> 23807076 |
Kevin D'Ostilio1, Julien Cremers, Valérie Delvaux, Bernard Sadzot, Gaëtan Garraux.
Abstract
While it is increasingly recognized that voluntary movements are produced by an interaction between conscious and unconscious processes, the role of the latter in Parkinson's disease has received little attention to date. Here, we administered a subliminal masked prime task to 15 Parkinson's disease patients and 15 age-matched healthy elderly subjects. Compatibility effects were examined by manipulating the direction of the arrows and the interstimuli interval. Analysis of the positive compatibility effect revealed performance differences between the most and the least affected hand in Parkinson's disease patients. Additionally, patients did not show the same tendency toward a negative compatibility effect as compared to elderly controls. These novel findings provide evidence supporting the role of basal ganglia circuits in controlling the balance between automatic motor response facilitation and inhibition.Entities:
Mesh:
Year: 2013 PMID: 23807076 PMCID: PMC3695560 DOI: 10.1038/srep02095
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Summary of subliminal motor processes predicted in healthy elderly controls and PD patients (in comparison to normal effects in young healthy subjects). Expected effect: delay in the occurrence of the NCE for elderly controls (300 ms instead of 150 ms) but no NCE for PD patients
| Young healthy subjects | Healthy elderly subjects | Parkinson's disease patients | |
|---|---|---|---|
| PCE | PCE | PCE | |
| NCE | |||
| NCE tendency |
PCE (positive compatibility effect): TR incompatible trials > TR compatible trials.
NCE (negative compatibility effect): TR incompatible trials < TR compatible trials.
Figure 1Graphical representation of classical compatibility effects (incompatible RT –compatible RT) in young healthy subjects and expected effects in elderly healthy subjects and Parkinson's disease (PD) patients.
Figure 2Mean RTs (a). and accuracy rates (b). for every conditions of each group.
A global PCE at ISI-0 in Parkinson's disease patients (PD) patients and age-matched controls (AC) and a change toward inhibition pattern for AC but not for PD at longer ISI are observed, suggesting an impaired motor inhibition process in PD. Vertical bars represent standard errors.
Figure 3Compatibility effects for each ISIs in Parkinson's disease patients (PD) and age-matched controls (AC).
* p < 0.05.
Figure 4Comparison between the most (MAH) and least affected hand (LAH) in PD patients for the facilitation effect (Neutral – compatible RTs) and conflict effect (Incompatible – neutral RTs).
Demographic and clinical data
| Patients | Age (years) | Gender | Global RT (ms) | Most affected hand | UPDRS part III | Disease duration (years) | Total score MATTIS (max 144) | Medications (LED-mg) |
|---|---|---|---|---|---|---|---|---|
| 1 | 70 | M | 884 | left | 20 | 14 | 127 | 400.25 |
| 61 | M | 444 | left | 13 | 9 | 136 | 711 | |
| 62 | F | 434 | right | 23 | 11 | 135 | 364.62 | |
| 56 | F | 551 | right | 24 | 7 | 142 | 527.25 | |
| 78 | M | 479 | left | 19 | 17 | 133 | 444.5 | |
| 50 | F | 531 | right | 4 | 12 | 144 | 1897.5 | |
| 65 | M | 394 | left | 17 | 9 | 140 | 185 | |
| 78 | M | 417 | right | 30 | 14 | 128 | 953.75 | |
| 69 | M | 588 | right | 22 | 16 | 137 | 830.75 | |
| 76 | M | 575 | right | 15 | 6 | 133 | 627.5 | |
| 72 | M | 526 | left | 25 | 14 | 136 | 418.75 | |
| 75 | F | 523 | right | 17 | 15 | 141 | 662.5 | |
| 67 | M | 479 | left | 21 | 7 | 134 | 452.25 | |
| 65 | F | 601 | right | 18 | 7 | 138 | 132 | |
| 72 | M | 416 | right | 18 | 9 | 138 | 248.5 | |
| Control Subjects | ||||||||
| 67 | F | 453 | ||||||
| 72 | M | 470 | ||||||
| 67 | F | 430 | ||||||
| 72 | F | 412 | ||||||
| 72 | M | 425 | ||||||
| 73 | F | 440 | ||||||
| 75 | F | 493 | ||||||
| 79 | M | 451 | ||||||
| 54 | M | 401 | ||||||
| 53 | F | 351 | ||||||
| 55 | F | 399 | ||||||
| 60 | M | 406 | ||||||
| 79 | F | 447 | ||||||
| 55 | F | 393 | ||||||
| 59 | M | 460 |
*LED = Levodopa Equivalent daily Dose.